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ABSTRACT 
PROSTACYCLIN AND THROMBOXANE A2 IN THE 
ATHEROSCLEROSIS SUSCEPTIBLE AND SUPER 
SUSCEPTIBLE WHITE GARNEAU PIGEON 
Director 
Janet Melvin Royer 
Morehead State~si 
of Thesis: 
Two strains of the White C pigeon, the 
atherosclerosis susceptible random bred White Garneau· 
(RBWC) and the super susceptible White Garneau II. 
(WC-II), were used to investigate the opposing roles 
of prostacyclin (PGI2) and thromboxane A2 (TXA2) in· 
the development of atherosclerosis. Since TXA2 is 
produced by platelets, platelet counts were determined 
to rule out the influence of platelet number on the 
production of TXA2 . There ~as no statistical dif-
ference in the means of the two strains, therefore any 
differences in TXA~ levels were true differences. ,. 
Plasma and aorta samples were tested for their levels 
of 6-keto-prostaglandin F1a (6-keto-PGF1a), t~:~stable 
metabolite of PGI2 , by radioimmunoassay (RIA>°.t ;·simul-
taneously plasma and platelet rich plasma (PRP)c. samples 
were evaluated by RIA for their levels of thromboxane 
B2 (TXB2), the stable metabolite of TXA2 . It was 
found that the more susceptible WC-II pigeon generated 
iii 
. -
more TXB2 than the RBWC. The WC-II also produced a 
significantly higher amount of 6-keto-PGF1a when given 
arachidonic acid stimulation. This would indicate that 
the super susceptible WC-II exhibits a defense 
mechanism to the progression of atherosclerosis by the 
increased ability to synthesize PGI2 in response to 
increased levels of TXA2 . 
Accepted by: 
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INTRODUCTION 
Atherosclerosis is a principle cause of heart 
disease. Recently Hopkins and Williams (1981) have 
compiled 246 factors associated with atherosclerosis 
and coronary heart disease, and grouped these into four 
categories: the initiators which unde=ine the integ-
rity of the arterial endothelium, the promoters which 
promote the buildup 0£ cholesterol, the potentiators 
which.increase the likelihood of thrombi and potenti-
ates the previous two, and the precip'itators which in-
duce acute ischemic events or arrhythmia and precipitate 
a heart attack. 
Due to the prevalence of atherosclerosis and 
heart disease, a great deal of research has been con-
ducted on the factors that constitute these four cate-
gories in the United States and abroad. 
This study deals with the roles of prostacyclin 
and thromboxane A2 in the susceptibility to atheroscle-
rosis. The White Garneau pigeon was the animal model 
selected to use in this investigation. The hypothesis 
for this study will be developed throughout the review 
of the literature, and stated along with the objectives 
and means to achieve these objectives at the end of 
the introduction. 
1 
Atherosclerosis seems to be initiated by 
factors that alter the endothelial cell lining of vas-
cular tissues, such as hyperlipidemia, certain metab-
olites, infectious agents or immunological injury, 
thus exposing the subendothelial collagen layer (Ross, 
Glomset, and Harker, 1977). When exposed ·to the sub-
endothelium, blood platelets adhere, then aggregate 
and release the contents of their granules (Ross and 
Glomset, 1976). This is followed by smooth muscle 
cell (SMC) proliferation, and the synthesis and depo-
sition of collagen fibrils, elastic fibers, proteo-
glycans, and lipids (Harker, Ross, Slichter, and 
Scott, 1976). These events ultimately lead to the 
formation of a primary lesion. The primary lesion 
formation may be prevented by inhibition of platelet 
consumption (Harker, et al., 1976). 
2 
If the source or sources of intimal injury 
persists then additional SMC proliferation will occur 
along with added connective tissue and lipid deposition 
(Ross and Glomset, 1976), leading to the atherosclerotic 
plaque and narrowing of the vascular internal diameter. 
The interaction between the damaged vascular 
wall and platelets results in the release from the 
platelets of the prostaglandin derivative, thromboxane 
3 
A2 (TXA2) (Gryglewski, Bunting, Moncada, Flower, and 
Vane, 1976). The Gryglewski and Moncada research teams 
proposed that a critical balance exists in the formation 
of thrombi between the TXA2 formed by the platelets and 
a substance initially called prostaglandin X (prosta-
cyclin) produced by the vascular walls from the 
endoperoxides, prostaglandins G2 and H2 . These endo-
peroxides may be produced by the stimulation of vaso-
constriction, chemical irritation or injury to the 
vascular tissue, or the endoperoxides may be supplied 
by the platelets. The prostacyclin (PGI2) would act 
to prevent platelet aggregation in the vicinity of the 
affected vascular segment (Gryglewski, et al., 1976) 
as shown in Figure 1. 
It was later hypothesized by Gryglewski (1980) 
that the beginning of atherosclerosis is causally 
associated with a localized increase in lipid peroxides, 
which inhibit prostacyclin synthetase, since these 
lipid peroxides have been found in atherosclerotic 
arteries but absent in healthy arteries. It was further 
postulated by Gryglewski (1980) that arterial thrombi 
may be the result of the inability of the endothelial 
tissue to generate enough prostacyclin. This would 
allow platelets to adhere and release TXA2 , followed by 
I 
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Balance between PGiz and TXAz as described 
by Gryglewski (1976). 
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platelet aggregation and vasoconstriction as a result 
of the inhibition of the PGI2 synthetase enzyme by 
lipid peroxides, endothelial detachment, or polyme-
rizing fibrin preventing the interaction between 
platelets and endothelial cells. 
Prostacyclin, derived from arachidonic acid, 
is formed from endoperoxides by arterial microsomes, 
and is a potent inhibitor of platelet aggregation and 
a strong vasodilator. It has a short half-life and is 
rapidly converted to the stable biologically inactive 
prostaglandin (PG) product 6-keto-PGF1a (Gryglewski, 
et al., 1976; Bunting, Gryglewski, Moncada, and Vane, 
1976; Gryglewski, 1980). 
Various chemical compounds have been found to 
stimulate or inhibit the production of PGI2 . The 
synthesis of PGI2 is stimulated by the administration 
of estradiol and triidothyronine, but is inhibited 
by the administration of testosterone (Nakao, Chang, 
Hurota, and Orimo, 1981). Furthermore, aortas from 
animal models with vitamin E deficiency produced less 
PGI2 , and TXA2 production by the platelets was 
increased in these animals upon stimulation by 
collagen (Karpen, Merola, Trewyn, Co=well, and 
Panganamola, 1981). 
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Thromboxane Az has a half-life of about thirty-
five seconds in aqueous solution and is rapidly con-
verted to the stable biologically inactive thromboxane 
Bz (TXBz) (Nelson, Kelly, Schneider, 1977). There is 
a high rate of conversion of endoperoxides to TXA2 by 
the microsomal fraction of platelets and lung tissue. 
Thromboxane is a potent platelet aggregator as well 
as a vasoconstrictor (Hamberg, Svensson, and 
Samuelsson, 1975; Samuelsson, Granstrom, Green, 
Hamberg, and Hammerstrom, 1975; Samuelsson, Goldyne, 
Granstrom, Hamberg, Hammerstrom, and Malmsten, 1978). 
Both PGI2 and TXA2 are synthesized from the 
same endoperoxides. Prostaglandin G2 (PGG2) and 
prostaglandin H2 (PGH2) are synthesized from the 20-
carbon fatty acid, arachidonic acid, by the cyclo-
oxygenase enzyme system. The cyclo-oxygenase can be 
inhibited by aspirin and indomethacin (Gryglewski, et 
al, 1976). The endoperoxides are then converted to 
PGI2 or TXA2 by prostacyclin synthetase and thrombcxane 
synthetase respectively (Samuelsson, et al., 1975;· 
Samuelsson, et al., 1978; Dusting, Moncada, and Vane, 
1979; Gryglewski, 1980) as outlined in Figure 2. 
Moncada and Vane (1977) proposed that the endo-
peroxides generated by platelets are utilized by the 
6 
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Figure 2. Biosynthesis of prostacyclin and thrombox-
ane. A2 as compiled from Gryglewski (1980) 
and Dusting, Moncada, and Vane (1979). 
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vessel enzymes to make PGI2 which prevents platelets 
from adhering to normal vessel walls. In their experi-
ment, arterial rings perfused with platelet rich plasma 
(PRP) g~µerated PGI2 . Arterial rings pretreated with 
indomethacin, a cyclo-oxygenase inhibitor, and then 
perfused with PRP produced PGI2 . They concluded that 
the cells of the vascular wall were able to utilize the 
platelet endoperoxides for the production of the PGI2 . 
Subsequently, any inhibition in the ability to synthe-
size PGI2 would remove the "inert" or repellent effect 
of this· prostaglandin. 
In the same year it was demonstrated, by 
Samuelsson (1977) from a patient suffering from a 
deficiency of platelet cyclo-oxygenase, that no plate-
let aggregation would occur, thus indicating the need 
for available endoperoxides to synthesize TXA2 . 
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Earlier it was pointed out by Ellis, Oelz, 
Roberts, Payne, Sweetman, Niess, and Oates (.1976) that 
the TXA2 released in the area of the damaged endo-
thelium causes arterial constriction and therefore 
cardiac complications simply by being a vasoconstrictor. 
Although the hypotheses by Gryglewski, et al., 
(1976) and Moncada and Vane (1977) on the generation 
of PGI2 have been widely accepted, variations of these 
basic proposals exist. One such proposal states that 
the blood vessels can "steal" the platelet endoper-
oxides, in particular the PGH2 , but only when there is 
endothelial damage, not as a normal coursa of events 
in platelet repulsion (Sivakoff, Pure, Hsueh, and 
Needleman, 1979). In addition, the atherosclerotic 
plaque decreases the vessel's ability to synthesize 
PGI2 and thereby reduces its defense capabilities. 
9 
Hamstra, Haddeman, and Don (1979) stated that 
vessels treated with indomethacin should generate PGI2 
when supplied with endoperoxides as previously reported. 
However, upon repeating the experiment by Sivakoff, 
et al., they found that there was no synthesis of PGI2 . 
They explained this incongruency by proposing that 
indomethacin binds reversibly to the cyclo-oxygenase 
enzyme and the vessels were then able to utilize their 
own prostaglandin endoperoxides after a greater period 
of time. 
More recently it has been proposed that the 
platelet derived growth factor (PDGF) released from the 
platelet granules upon aggregation stimulates the 
production of PGI2 (Coughlin, Moskowitz, Zetter, 
Antoniades, and Levine, 1980). Paralleling this finding 
was another from a study of platelets that had undergone 
10 
freeze etching. This showed that the lack of platelet 
proturberances caused by PGI2 brought about a 
stabilizing effect, thereby regulating the release of 
PDGF from the platelets and thus controlling the pro-
liferation of SMC (Weber, Bianciardi, Toti, and 
Sinzinger, 1981). Since the proliferation of SMC tis-
sue accompanies the development of the atherosclerotic 
lesion, these two studies suggest a feedback mechanism. 
In yet another study it was demonstrated that 
PRP treated with aspirin, a cyclo-oxygenase inhibitor, 
could stimulate aortic strips to generate 6-keto-PGF1a, 
the stable metabolite of PGI2 . So some factor other 
than platelet endoperoxides was responsible for its 
synthesis of 6-keto-PGF1a. These may be such factors 
as PDGF and the mechanical impact of the platelets on 
the endothelial cells (Galli, Petroni, Socini, Agradi, 
Colombo, Folco, and Tremoli, 1981). This idea of 
mechanical impact was expanded by Korbut, Boyd, and 
Eling (1982) when they proposed that it was the action 
of the platelet to disturb the vascular wall cell 
membrane, which in turn stimulates phospholipase to 
cleave arachidonic acid from the vascular cell membrane 
bound phospholipids. The free arachidonic acid is then 
converted by the vascular cell microsomes to PGI2 . 
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Whatever the source or sources of the generation 
of prostacyclin, it has been shown experimentally that 
PGI2 and TXA2 piay opposing roles in atherogenesis. 
Da-ca collected on various mammalian· species indicate 
that species more susceptible to atherosclerosis pro-
duce smaller amounts of PGI2/mg tissue wet weight/minute 
than less susceptible species (Sinzinger, Clopath, 
Silberbaurer, and Winter, 1980). 
In the atherosclerotic rabbit the platelets 
were noted to produce two times more TXB2 than platelets 
from controls within a five minute incubation with 
arachidonic acid. In addition, the ability of the PGI2 
to inhibit the formation of TXB2 in intact platelets 
was more pronounced in atherosclerotic rabbits 
(Dembrinska-Kiec, Ricker, and Schonhofer, 1979), showing 
an increased sensitivity as part of a defense mechanism. 
It was also evidenced that the conversion of arachidonic 
acid to 6-keto-PGF1a in the atherosclerotic rabbit 
heart tissue was suppressed by as much as 40% of the 
controls. The aortic rings of these animals synthesized 
less prostacyclin than the controls (Dembinska-Kiec, 
Gryglewski, Zmuda, and Gryglewski, 1977). These experi-
ments reflect the hypotheses, stated in various forms 
earlier that the inability to generate adequate amounts 
of PGI2 leads to the greater synthesis of TXA2 and 
ultimately to hemostatic irregularities. 
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Another animal that has been used as a model in 
the study of atherosclerosis is the pigeon. Certain 
breeds of the pigeon tend to be resistant to athero-
sclerosis while others are susceptible to the sponta-
neous development of the disease. The Show Racer 
pigeon is resistant while the White Garneau will 
develop spontaneous atherosclerosis (Lofland and 
Clarkson, 1960). 
Nearly 100% of the White Garneau pigeons have 
macroscopic aortic lesions by the age of three years 
with severity correlated to age, and these lesions are 
more numerous and severe in the lower half of the 
thoracic aorta where the celiac artery emerges. These 
lesions are typically made up of cholesterol, other 
lipids, collagen, and smooth muscle cells (Prichard, 
Clarkson, Goodman, and Lofland, 1964). Between nine 
to twelve months of age, termed the critical period of 
sterol accumulation, there is a significant increase 
in the total sterol content of the White Garneau aorta 
as well as a doubling of the level of esterified 
cholesterol that is not detected in the Show Racer 
(Subbiah, Unni, Kottke, Carlo, and Dinh, 1976). 
. . 
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There is also microscopic evidence of plasma 
membrane ruffling and extensive endothelial desquamation 
occurring in the White Carneau prior to the critical 
period, becoming more pronounced with age. These sites 
are usually coupled to platelet aggregates (Lewis and 
Kottke, 1977). 
When compared to mammals the pigeon production 
of PGI2 is low, but interesting in that the production 
of 6-keto-PGF1a is significantly higher in the athero-
sclerosis susceptible White Carneau than in the resis-
tant Show Racer, when aorta homogenates were stimulated 
with arachidonic acid (Subbiah, Schweiger, Deitmeyer, 
Gallon, and Sinzinger, 1980). This finding is somewhat 
in opposition to that reported to occur in mammalian 
species; however, an explanation would be conjectural 
since TXA2 was not determined by Subbiah's study. 
The White Carneau pigeon is an excellent choice 
for an animal model in the study of atherosclerosis, 
since it, like the human, develops spontaneous athero-
sclerosis. Interpreting the def·inition of atherosclero-
sis supplied by the World Health Organization, Prichard, 
et al., (1964) concluded that only the human, the pigeon, 
and a few long-lived birds maintained at zoos developed 
lesions that satisfied the requirements of intimal 
14 
changes consisting of the accumulation of lipids, carbo-
hydrates, blood and blood products, fibrous tissue, and 
calcium associated with medial changes. 
The White Garneau pigeon may also exhibit an 
intricate defense mechanism in response to atherogen-
esis. Thus the roles of PGI2 and TXA2 may be examined 
in this relation to the differences in susceptibility 
of pigeons. 
The purpose of this study was to test the 
hypothesis that in atherosclerosis there is a correla-
tion of decreased synthesis of PGI2 in response to the 
increased production of TXA2 . The objectives of this 
study were to determine the differences; if any, in the 
unstimulated and arachidonic acid stimulated levels of 
PGI2 and TXA2 in atherosclerosis susceptible and super 
susceptible White Garneau pigeons. To achieve these 
objectives, pigeons of both strains of the White 
Garneau were purchased from the Bowman Gray Medical 
School at Wake Forest University, Winston-Salem, North 
Carolina. Radioimmunoassay was used to determine PGI2 
and TXA2 . Plasma samples from both strains were 
examined for platelet count to eliminate the influence 
of platelet number on the production of TXA2 . Platelet 
rich plasma and aorta samples of both strains, with and 
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without arachidonic acid stimulation were tested for 
levels and TXA2 and PGI2 respectively. Therefore, the 
analysis of these assays would indicate differences in 
the abiltty to synthesize these two compounds, TXA2 
and PGI2 , inherent to the strain. 
MATERIALS AND METHODS 
Animal Sel·ection and Care 
Fifteen atherosclerosis susceptible random bred 
White Garneau (RBWC) pigeons and fifteen super suscep-
tible Wh~te Garneau-II (WC-II) pigeons were obtained 
from the Bowman Gray Medical School at Wake Forest 
University (Winston-Salem, North Carolina) . The· 
pigeons ranged in age from one to fifteen months and 
included males and females. Two of the WC-II expired 
within two weeks of arrival, all others were housed in 
wire cages in groups or separately according to their 
compatibility in an animal room with approximately ten 
hours of darkness and fourteen hours of light simu-
lating natural conditions. All birds were maintained, 
ad libitum, on cholesterol free diets of Purina Pigeon 
Chow (Ralston-Purina Co.) consisting of approximately 
40 grams of food daily with adequate fresh water. 
Collection and Handling of Samples 
When collecting blood samples, the birds were 
held firmly on their sides, one wing extended and held 
in place, and the area of puncture was cleaned with an 
alcohol swab and dried with sterile cotton before with-
drawing sample. All blood samples were collected from 
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the alar vein of the wing using 10 cc syringes with 
22 gauge hypodermic needles to prevent clotting in the 
needle and unnecessary hemolysis of sample. Samples 
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of 1 to 2 ml were usually collected no more than one 
time per week to prevent undue stress on the birds. 
After collection, the blood was immediately transferred 
to silicon glass test tubes containing 4.4 mM EDTA, 
to obtain plasma to be used in the platelet count and 
in the formation of platelet rich plasma. Samples 
used for the radioimmunoassay of 6-keto-PGF1a and TXB2 
were immediately transferred after collection to sili-
con glass tubes containing 4.4 mM EDTA and indomethacin 
in the concentration of 1 µg/ml of blood. The indo-
methacin solution was prepared by adding 0.0264 grams 
of Tris HCl and 0.0403 grams of Tris base to 5.0 ml of 
distilled water at pH 8.4, then 1 mg of indomethacin 
was added. Next 0.0635 grams of Tris HCl and 0.0118 
grams of Tris base were mixed in 100 ml of dH20, and 
95 ml of this solution at pH 7.5 were added to the 5 ml 
of the indomethacin solution. For each ml of blood 
collected 0.1 ml of this final solution was used. 
Blood samples to be used for the platelet count 
were processed within thirty minutes after collecting. 
Samples for the determination of levels of 
6-keto-PGF1~ and TXB2 were placed on ice until 
processed. 
Plasma was obtained by centrifuging the blood 
at 1500 rpm for five minutes in a clinical centrifuge 
and immediately removing the plasma from the packed 
cells. 
Aorta samples were collected by sacrificing 
the bird via injection of excess Nembutal (Abbott Co.) 
and then placing the head of the bird in a closed 
container saturated with diethyl ether. After this, a 
10 to 15 mm section of the aorta at the celiac origin 
was removed and placed on ice. These samples were 
processed within minutes of removal. 
Platelet Count 
18 
The Rees and Ecker method was employed for the 
platelet count. The Rees and Ecker solution was pre-
pared by adding 1.0 gram of brilliant cresyl blue (Sigma 
Chemical Co.), 3.8 grams of sodium citrate, and 0.2 ml 
of 40% formaldehyde in a final volume of 100 ml. This 
solution was prepared fresh and filtered before each 
use. 
The platelet count was determined from the 
plasma which was removed from the packed cells with a 
Pasteur pipet, and placed in labelled disposable test 
tubes. Using the red blood cell pipet supplied with 
the hemocytometer (Spencer Optical Co.), the plasma 
19 
was drawn to the 0.5 mark. The Rees and Ecker solution-
was drawn to the 101 mark and the pipet gently shaken 
for three minutes. The first five drops were dis-
charged from the pipet, the chambers on the hemocyto-
meter charged, and the hemocytometer placed in a 
covered petri dish containing moist cotton balls for 
five minutes to allow the platelets to settle while 
preventing excessive evaporation. The hemocytometer 
was then placed on the stage of a microscope and 
observed at a magnification of 400. The platelets, 
appearing as small glistening bodies, were counted in 
the five sections used for the red cell count. This 
number was then multiplied by 200 (dilution correction 
factor) and then by 50 (volume correction factor) to 
yield the total number of platelets per mm3 of plasma 
(Seiverd, 1972). All samples were counted in duplicate 
and the average was recorded. 
Extraction of Samples 
All samples for radioimmunoassay (RIA) were sub-
jected to extraction procedures to remove proteinaceous 
materials that might interfere with the assays (Green, 
Hamberg, Samuelsson, and Frolich, 1978). The extrac-
tion procedures presented are·modifications of those 
used by Yamamoto, 0gino, 0hki, and Yoshimoto (1977); 
Dembinska-Kiec, et al., (1977); and Granstrom and 
Kindahl (1978). 
Samples were placed in glassware siliconized 
with a 5% solution of dimethyldichlorosilane, or in 
polypropylene test tubes. Disposable polypropylene 
pipet tips were also used in transferring the samples 
since prostaglandins adhere to unsiliconized glass 
surfaces. 
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To test for circulating levels of 6-keto-PGF1a 
and TXB2 by RIA, 0.5 ml aliquots of plasma were removed 
from the packed cells and placed in clean, siliconized 
test tubes. The sample was chilled on ice, acidified 
to pH 3.0 with 1 N HCl, and extracted in five volumes 
of ethyl acetate. This solution was mixed with a 
Vortex mixer, allowed to separate, and the organic 
layer removed to the flask of a roto-evaporater. The 
ethyl acetate was then evaporated rapidly under reduced 
pressure and constant temperature by immersing the 
evaporating chamber in a water bath. The residue was 
then redispersed in 1 ml of the RIA buffer (New England 
Nuclear) consisting of 50 mM phosphate buffer at pH 6.8 
21 
with 0.1% gelatin and 0.01% thimersol as preservatives. 
The solution was transferred to a polypropylene tube, 
capped, and frozen until time of assay. 
Platelet rich plasma samples were extracted by 
using two 0.25 ml aliquots of plasma from each pigeon 
tested, and centrifuging these tubes at 3000 rpm for 
fifteen minutes to form platelet pellets. Excess plasma 
was removed from these pellets. One ml of phosphate 
buffered saline, pH 7.4, with 5.5 mM glucose was added 
to one tube. Then one ml of the phosphate buffered 
saline with arachidionic acid (Sigma Chemical Co.) in 
the concentration of 2.5 µg/ml was added to the second 
tube. These two samples were incubated for three min-
utes at room temperature, and a platelet count was 
performed so that the TXB2 levels could be expressed as 
picograms per 108 platelets. The incubation period was 
terminated by chilling and acidifying to pH 3.0 with 
1 N HCl. The samples were then extracted with five 
volumes of ethyl acetate and processed as described for 
the plasma sample. 
After sacrificing, a section of aorta was 
removed from each bird, immediately placed on ice, and 
cut into two pieces of approximately equal size of about 
5 to 8 mm in length. Excess adipose tissue was removed 
22 
from the pieces, then they were rinsed in phosphate 
buffered saline containing 5.5 mM glucose, blotted dry, 
and weighted. One ring was added to a solution of 15 mM 
Tris HCl, pH 7.4, containing 140 mM NaCl and 5.5 mM 
glucose in the amount of 1 ml of solution per 20 mg 
tissue (wet weight). The second ring was placed in this 
solution containing 2.5 µg/ml arachidionic acid in the 
amount of 1 ml of solution per 20 mg tissue (wet weight). 
The rings were incubated for five minutes and the incu-
bation was terminated by chilling and acidifying to pH 
3.0 with 1 N HCl. These solutions were extracted with 
five volumes of ethyl acetate and treated as described 
for the plasma sample. 
The RIA tracer solutions of tritiated 
6-keto-PFG1a and TXB2 were also extracted according to 
the procedure for plasma to determine the percent 
recovery of this method. 
Radioiinmilhoassay for 6-keto-PGF1·a and TXB2 
Assays for the level of 6-keto-PGF1a in the 
plasma and aorta samples were carried out simultaneously 
with assays for the level of TXB2 in the plasma and PRP, 
according to the specifications of the producers of the 
RIA materials (New England Nuclear). Samples were 
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pipetted using a micropipettor with polypropylene dispo-
sable tips and processed in polypropylene tubes. 
The RIA assay buffer (see Table 1) was added to 
the appropriate tubes. To these, standard, control, or 
sample were added 1 followed by tracer and mixed. The 
tracer solution was composed of 1 µCi of tritated pros-
taglandin in 50 mM phosphate buffer at pH 6.8. Then 
the antiserum, produced by New England Nuclear in rab-
bits against a bovine serum albumin conjugate of the 
prostaglandin, was added, mixed, and incubated for 
sixteen hours at 4° C. 
After the incubation period, 500 µl of charcoal 
suspension was added to all tubes except the total count 
tubes and incubated for 15 minutes at 4° C. Only eight 
samples were processed at one time to prevent exceeding 
the maximum time of thirty minutes allowed, to avoid 
excessive stripping of bound prostaglandin. After the 
fifteen minute period, these tubes were centrifuged at 
l000Xg for ten minutes and decanted into scintillation 
vials. Five ml of scintillation cocktail (Atomlight, 
New England Nuclear), used to absorb the excitation 
energy from the beta decay, was added to each vial. 
The vials were counted in a scintillation counter 
(Packard model 300C). 
Total Counts 
Blank 
"O" Standard 
Standards 
Human Plasma Control 
(0 ng/ml) 
Human Plasma Control 
(1 ng/ml) 
Samples 
Tube No. Buffer Standard Samples Tracer Antibody 
1-2 
3-4 
5-6 
7-18 
19-20 
21-22 
23,24 etc. 
900 
400 
300 
200 
200 
200 
200 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
Table 1. Assay protocol for the RIA of 6-keto-PGF1q with all volumes expressed 
in microliters (New England Nuclear, 1980). 
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Determination of Values from Scintillation Counts 
Using the counts per minute (cpm) obtained from 
the counter, the disintegrations per minute (dpm) were 
calculated by adjusting.for the efficiency of the sys-
tem. The efficiency is a function of the quinching 
factor derived from the amount of light energy absorbed 
by non-light producing substances such as the sample. 
Therefore, the cpm divided by the efficiency of the 
system yields the dpm. The dpm is then used to deter-
mine the picogram yield of the standards, controls, 
and samples as shown in Figure 3. 
1. Average net count= average standard or sample count minus average 
blank count. 
2. % Bound= average net count 
3. 
average net of total count tubes 
Normalized % Bound (%B/B ) = % B of standard "or s·ample 
0 % B of zero standard X 100 
Figure 3. Calculations for the determination of picogram values in 
standards, controls, and samples (New England Nuclear, 1980). 
N 
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RESULTS 
To determine that any differences detected in 
the levels of thromboxane in the two strains were true 
differences in the rate of synthesis and pot because of 
elevated platelet number, a platelet count was performed. 
Ten pigeons of each strain were randomly selected. The 
average count for each bird is summarized in Table 2. 
The RBWC had a mean count of 522,000/mm3 of plasma with 
a standard deviation (S-) of 1.137 x 105 while the WC-II 
. X 
had a mean count of 524,000/mm3 , Sx = 0.901 x 105 . Using 
the analysis of variance (ANOVA) statistical test, these 
means were not found to be significantly different. 
The next parameter of study was the RIA for 
6-keto-PGF1~, the stable metabolite of PGI2 , in plasma 
and aorta samples, and the RIA for TXB2 , the stable 
metabolite of TXA2 , in plasma and PRP samples. Four 
atherosclerosis susceptible RBWC and four super suscep-
tible WC-II pigeons were selected to be tested for 
these substances throughout the investigation. These 
pigeons were selected by age, ranging from nine to 
nineteen months, to coincide with the critical period 
of sterol accumulation. 
The calculated normalized percent bound values 
of the standards, expressed on three cycle semi-
27 
Age 
(months) 
16 
11 
11 
8 
8 
8 
8 
8 
7 
6 
Table 2. 
PLATELET COUNT 
RBWC WC-II 
Platelet Count/mm3 Age 
(months) 
Platelet Count/mm3 
460,000 29 490,000 
600,000 19 520,000 
710,000 17 400,000 
430,000 9 410,000 
460,000 8 640,000 
333,000 7 590,000 
520,000 6 430,000 
620,000 5 540,000 
470,000 5 580,000 
620,000 5 640,000 
Platelet counts for the random Bred White Carneau (RBWC) and the 
White Carneau-II (WC-II) pigeons. (RBWC- X = 522,000, S- = 1.137 x 5 . 5 X 
10 ; WC-II- X = 524,000, S; = 0.901 x 10 ). 
N 
00 
logarithmic graph paper illustrating standardization 
curves for 6-keto-PFG1a and TXB2 , are indicated on 
Graphs 1 and 2. It should be noted that all values 
expressed for the _RIA are not in vivo levels, but are 
indicative of these levels and certainly may be used 
as a basis of comparison between these two strains of 
the White Garneau pigeon. 
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The plasma was tested to become acquainted with 
what may be considered circulating levels of prostacy-
clin and thromboxane A2 as reflected by their metab-
olites, 6-keto-PGF1a and TXB2 respectively. These 
values, shown in Table 3, are expressed in picograms 
per ml of extracted fluid. 
The mean plasma levels of 6-keto-PGF1a for the 
RBWC (X = 36.00, S;; = 3.74) and for the WC-II (X = 
45.75, S;; = 12.01) showed no statistically significant 
difference using the ANOVA, but did indicate a tendency 
for the WC-II to have more 6-keto-PGF1a in circulation 
(F = 2.40, p = 0.172). The mean plasma levels of TXB2 
were not analyzed due to the extremely high values of 
two of the WC-II pigeons. Even though these results 
were probably due to experimental error, they most 
likely reflect elevated levels in the super susceptible 
WC-II. 
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0
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PICOORAHS 
The standard curve for TXBn derived by plotting the normalized 
L. 
percent bound (%B/B
0
) against the known picogram values of the 
standards. 
RBWC 
WC-II 
Age 
(months) 
12 
17 
12 
9 
18 
19 
10 
9 
6-keto-'PGF1a 
(pg/ml) 
31 
36 
37 
40 
62 
44 
44 
33 
TXB2 
(pg/ml) 
9 
25 
17 
20 
310 
280 
12 
22 
Table 3. Plasma levels of 6-keto-PGF1a and TXB 2 
expressed in picograms per ml extraction 
fluid of the random bred White Garneau 
(RBWC) and the White Garneau-II (WC-II). 
(RBWC- X = 36.00, S- = 3.74; WC-II- X = 
X 
45.75, S; = 12.01 for 6-keto-PGF1a). 
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The levels of TXB2 generated by the PRP of the 
two strains were examined with and without arachidonic 
acid stimulation. These values, shown in Table 4, are 
expressed in picograms per 108 platelets. The TXB2 
level of the PRP without arachidonic acid stimulation 
was significantly higher in the WC-II (X = 19.5, Sx = 
19.9) than in the RBWC (X = 5.3, Sx = 1.8), F = 7.52, 
p = 0.05. The TXB2· level of the PRP with stimulation 
showed a tendency to be higher in the WC-II as well, 
(WC-II- X.= 66.25, Sx = 67.54; RBWC- X = 14.32, Sx = 
6.8) with F = 2.34, p = 0.17 . 
.Analyzation of the aorta samples, shown in 
Table 5 as picograms per mg of aorta wet weight, indi-
cated no difference in the amount of 6-keto-PGF1a 
between the RBWC (X = 5.687, S- = 2.27) and the WC-II 
X 
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(X = 8.32, Sx = 4.75) without arachidonic acid stimu-
lation. However, the WC-II did synthesize significantly 
higher amounts of 6-keto-PGF1a upon stimulation by 
arachidonic acid (WC-II- X = 13.40, Sx = 4.49; RBWC-
X = 5.43, Sx = 2.17), F = 10.19, p = 0.018. 
Testing the correlation of the production of 
the 6-keto-PGF1a to the production of TXB 2 using the 
Pearson r correlation coefficient, showed a strong 
co~relation (r = 0.643, df = 7, p = 0.1) for the aorta 
RBWC 
WC-II 
Age 
(months) 
12 
17 
12 
9 
18 
19 
10 
9 
TXB 2 Without A.A. 
Stimulation (pg/108) 
7.65 
5.00 
3.23 
5.33 
47.92 
18.82 
5.20 
6.25 
TXB2 With A.A. 
Stimulation (pg/108) 
12.94 
24.21 
8.82 
11. 33 
58.33 
17.06 
164.00 
25.63 
Table 4. Platelet rich plasma levels of TXB2 of the random bred White Garneau 
(RBWC) and the White Garneau-II (WC-II), with and without· arachidonic 
acig (A.A.) stimulation, expressed in picograms per 108 platelets. 
[(RBWC - without A.A. - X = 5.3, Sx = 1.8; WC-II - without A.A. -
X = 19.5, Sx = 19.9), (RBWC - with A.A. - X = 14.32, Sx = 6.8; 
WC-II - with A.A. - X = 66.25, Sx = 67.54)]. 
RBWC 
WC-II 
Age 
(months) 
12 
17 
12 
9 
18 
19 
10 
9 
6-keto-PGF1a Without A.A. 
Stimulation 
5.69 
5.71 
2.89 
8.46 
4.48 
15.26 
6. 43 
7.11 
(pg/mg) 
6-keto-PGF1a 
Stimulation 
8.06 
4.00 
3.33 
6.33 
9.09 
16.66 
17.86 
10.00 
With A.A. 
(pg/mg) 
Table 5. Aorta ring levels of 6-keto-PGF1a of the random bred White Garneau 
(RBWC) and the White Garneau-II (WC-II), with and without arachidonic 
acid (A.A.) stimulation, expressed in picograms per mg (wet weight). 
[(RBWC - without A.A. - X = 5.687, S- = 2.27; WC-II - without A.A. -
X 
X = 8.32, Sx = 4.75), (RBWC - with A.A. - X .= 5.43, Sx = 2.17; 
WC-II - with A.A. - X = 13.40, S- = 4.49)]. 
X 
w 
Ln 
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rings stimulated with arachidonic acid to the stimulated 
PRP for all the pigeons tested. In addition, the 
plasma levels of 6-keto-PGF1a and TXB2 for all cases 
showed a significant correlation (r = 0.796, df = 7, 
p = 0.05). Therefore, as the amount of TXB2 increased 
in the pigeons, so did the amount of 6-keto-PGF1a. 
In order to test whether there were any differ-
ences in the ability of each strain to synthesize PGI2 
in response to TXA2 , the mean ratios of 6-keto-PGF1a/ 
TXB2 were analyzed between strains using the ANOVA at 
the 0.05 level of significance. Analysis for all 
samples showed no significant differences. 
Finally, to determine the relationship of 
arachidonic acid to the susceptibility of athero-
sclerosis, the ratios of 6-keto-PGF1a/TXB2 with and 
without arachidonic acid stimulation were examined 
within rather than between the two strains of the 
White Carneau pigeon. The mean ratio of 6-keto-PGF1a 
to TXB2 without 
S;; = 0. 386, and 
stimulation for the RBWC was 1.075 with 
with stimulation, X = 0.45, S- = 0.19. 
X 
Using the ANOVA, the mean ratio without stimulation 
was found to be significantly higher (F = 8.408, p = 
0.05), than the mean ratio with stimulation. The 
mean ratios for the WC-II without (X = 0.8, S- = 0.496) 
X 
. -
and with arachidonic acid (X = 0.4, Sx = 0.403) were 
not statistically different at the 0.05 level. 
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DISCUSSION 
Although the White Carneau pigeon has been 
widely used in the study of atherosclerosis, little 
has been published about the super susceptible WC-II. 
Therefore, this investigation is important as well as 
interesting because of the more pronounced character-
istics exhibited by the WC-II. 
The platelet count showed no evidence of 
differences in platelet number among the pigeons, and 
since PGI2 has been shown not to-influence the platelet 
count (Gryglewski, 1980), it may be concluded that the 
differences observed in the measured levels of TXB2 
reflect true differences in the amounts of TXA2 
generated by the platelets. 
Even though the plasma levels of PGI2 and TXA2 
were inconclusive of differences in the two strains, 
it is important to remember that the level of PGI2 
was significantly correlated to TXA2 . So as the level 
of one increased, so did the other in a near one-to-one 
relation. Therefore, whatever the source or cause of 
the increasing levels of TXA2 in pigeons, it stimu-
lated an increased production of PGI2 . 
Adding to these observations, it is evident 
that the platelets of the super susceptible WC-II, 
38 
even without arachidonic acid stimulation, were able 
to synthesize a significantly higher amount of TXA2 
39 
in the three minute incubation period than the plate-
lets of the RBWC. This would indicate that whatever 
the trigger mechanism, the platelets of the super 
susceptible pigeons have a highly active enzyme system 
producing larger amounts of TXA2 than the platelets 
of the less susceptible pigeons. It seems reasonable 
', 
to assume that this mechanism must be directly involved 
with the more pronounced susceptibility to athero-
sclerosis of the WC-II. 
When analyzing the response of the aorta 
tissue, it is interesting to note that the greater 
ability to utilize arachidonic acid to form PGI2 is 
not found in the less susceptible RBWC as would be 
expected, but rather in the super susceptible WC-II. 
This is the converse of what has been observed in 
mammals. In all RBWC and·WC-II tested, the synthetic 
ability of the aorta to form PGI2 increased as the 
ability of the platelets to form TXA2 increased. 
Examining the ratio differences of the 6-keto-
PGF1a/TXB2, with and without arachidonic acid stimu-
lation for both strains, it appears that the signif-
icantly higher ratio of the RBWC without/with stimu-
lation is indicative of this strain's ability to more 
effectively produce PGI2 in response to TXA2 . Even 
with a decreased substrate, the RBWC was able to 
produce larger amounts of PGI2 in response to TXA2 
than the WC- II. 
This would lead to the conclusion that the 
RBWC is the less. susceptible strain, in part, because 
of its ability to maintain higher levels of PGI2 with 
or without additional arachidonic acid availability 
in response to TXA2 production. Even though the WC-II 
shows an increased production of PGI2 when given 
arachidonic acid stimulation, it does not have the 
ability to maintain adequate PGI2 levels against the 
increased TXA2 . 
It was shown by Young and Middleton (J966) 
that the atherosclerosis resistant Show Racer male 
pigeons had significantly higher percentage of 
arachidonic acid of the serum sterol esters than the 
White Garneau male, and that the Show Racer females 
had a significantly higher percentage of arachidonic 
acid of the liver sterol esters than the White Garneau 
female pigeons. 
This leads to the conjecture that the super 
susceptible WC-II may lack available arachidonic acid 
40 
in the aortic tissue examined, thus contributing to 
its inability to maintain adequate PGI2 levels. 
41 
This coupled to the greater ability of the 
platelets of the WC-II to synthesize TXA2 without 
stimulation, reflecting in vivo conditions, adds to the 
differences in the susceptibility of the two strains. 
Therefore, the crit_ical balance between PGI2 
and TXA2 plays an instrumental role in the difference 
in susceptibility of these two strains of the White 
Garneau pigeon. 
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